Education only, not medical advice◆21+◆Every dose is an example to finalize with a licensed provider
HormonalHuman Menopausal Gonadotropin (FSH + LH Mixture)FDA-approved medicine
HMG
Human Menopausal Gonadotropin · Menotropin
Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.
75 IU (1 vial) per dose – 75 IUSubQDaily (fertility) or 2-3x weekly (TRT adjunct)
Urinary-Derived GonadotropinFDA-Approved (Menopur)Fertility Medicine + Off-Label TRT/PCT
HMG (Human Menopausal Gonadotropin) is a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women, who excrete high levels of these gonadotropins due to absent ovarian negative feedback. FDA-approved formulations include Menopur (Ferring) and historic Pergonal. Standard composition: 75 IU FSH + 75 IU LH per ampoule, with FSH:LH ratio approximately 1:1.
Quick Start
Route
Subcutaneous or intramuscular injection
Start low
75 IU SubQ
Frequency
Daily (fertility) or 2-3x weekly (TRT adjunct)
Timing
Independent
Starting dose. 75 IU — (1 vial) per dose
Per fertility specialist (cycle protocol) or endocrinologist (TRT/PCT). Reconstitute Menopur per label. Refrigerate.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
75 IU (1 vial) per dose · Subcutaneous or intramuscular injection · Daily (fertility) or 2-3x weekly (TRT adjunct)
conservative starter
75 IU (1 vial) per dose
Daily (fertility) or 2-3x weekly (TRT adjunct)
Expert
Spermatogenesis Induction
75 IU · SubQ · 3x Weekly
human clinical trial · FDA Menopur label
Far more effective for restoring sperm count than HCG alone because it contains FSH. Often used alongside HCG.
75 IU
3x Weekly
Reconstitution CalculatorU-100
050100u
Draw to
— units
◆
◆
◆
01
How it works
HMG provides exogenous gonadotropin stimulation to the gonads:
FSH Component
In females, FSH stimulates ovarian follicular development and granulosa cell estrogen production. In males, FSH stimulates Sertoli cells to support spermatogenesis - critical for fertility preservation during exogenous testosterone use.
LH Component
In females, LH triggers ovulation when sufficient follicular maturation has occurred and supports luteal phase progesterone. In males, LH stimulates testicular Leydig cell testosterone production - the primary mechanism for HCG/HMG use in maintaining testicular function during TRT.
Distinct From HCG
HCG (human chorionic gonadotropin) acts primarily as an LH-mimic with very long half-life (~24-30 hours) - drives Leydig testosterone production but provides minimal FSH support. HMG provides BOTH FSH and LH - more complete gonadotropin replacement, particularly relevant for spermatogenesis recovery in PCT contexts.
Pulse Pattern
HMG provides relatively sustained gonadotropin elevation rather than the pulsatile release of endogenous FSH/LH. This works clinically but may suboptimally mimic native physiology in some contexts.
Female Hyperstimulation Risk
In ovulation induction / IVF, excessive HMG response produces ovarian hyperstimulation syndrome (OHSS) - the dominant safety concern. Careful dose titration and monitoring with estradiol and ultrasound mitigate.
Male Use Specifics
TRT/PCT use targets testicular function maintenance. Combined with HCG (LH mimic) sometimes used for both rapid Leydig response (HCG) and sustained Sertoli/spermatogenesis support (HMG/FSH).
02
What to expect
Early
Days 1–7
Female fertility: ovarian response visible on ultrasound within 5-7 days. Male: gradual gonadotropin response over 2-4 weeks.
Mid
Weeks 2–4
Female: ovulation typically 10-14 days into cycle. Male: testicular size and testosterone improvements visible 4-8 weeks.
Later
Weeks 4–12
Long-term TRT adjunct: sustained testicular function maintenance with continued dosing.
03
Evidence
HumanStrong
AnimalStrong
In-vitroPresent
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Evidence boundary from the checked abstract: As menotropins were administered for progressively longer periods, the number of maturing follicles increased.
As menotropins were administered for progressively longer periods, the number of maturing follicles increased.
Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Dose/route: 75 IU (1 vial) per dose; Subcutaneous or intramuscular injection; Daily (fertility) or 2-3x weekly (TRT adjunct). No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
04
Side effects & safety
Commonly reported
Injection site reaction (mild)
Mild headache
Abdominal bloating (female - early ovarian response)
Flushing
Less common & notes
Ovarian hyperstimulation syndrome (OHSS) in females - dominant safety concern in fertility cycles.
Severe form (ascites, electrolyte disturbance, thromboembolism risk) requires hospitalization.
Mild OHSS resolves with cycle.
Gynecomastia in males if excessive aromatization.
Allergic reactions rare but documented (urinary-derived protein source).
Multiple pregnancy in fertility cycles (twins/triplets) - manageable risk with monitoring.
Long-term use of urinary-derived gonadotropins generally well-tolerated.
05
Pharmacokinetics
Illustrative plasma concentration · 34 h
Half-life
FSH ~20-30 hours; LH ~10-20 hours
Peak · Tmax
12-24 hours
Post-injection
Elimination
Days to weeks for sustained gonadal response
Bioavailability
subQ ~70%, IM similar
Duration of action
Daily or 2-3x weekly dosing typical
Clearance
Hepatic and renal
Storage. Lyophilized: refrigerate. Reconstituted: refrigerate, use within 28 days per Menopur label. Light-sensitive.
06
Regulatory status
FDA-approved as Menopur (Ferring) and historically Pergonal (Serono) for: female ovulation induction, IVF stimulation, male hypogonadotropic hypogonadism. Off-label use for TRT adjunct and PCT requires endocrinologist supervision. WADA prohibited under class S2 (peptide hormones) both in and out of competition - relevant for athletes.
Put it to work
Calculate, log & track
Open HMG straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.